Keywords: USA, PhRMA, Post-marketing surveillance, Rare diseases, Orphan drugs, Tufts

PhRMA clarifies initiative to evaluate existing medicines; comments on orphan drugs

Article | 25 January 2010

Following a report by the US drug sector newsletter The Pink Sheet that the Pharmaceutical Research and Manufacturers of America ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in